EGFR inhibitors square off at ASCO

Article Abstract:

The epidermal growth factor receptor (EGFR) inhibitors represent the first real market competition for the nascent targeted-cancer therapies and it provides a case study at the annual meeting of the American Society of Clinical Oncologists (ASCO) held on June 5-8, 2004. The antibody EGFR inhibitors target the extracellular portion of the receptor, whereas small molecule drugs tend to inhibit the intracellular tyrosine kinase domain.

Conferences, meetings and seminars, Tyrosine, Epidermal growth factor receptors, American Society of Clinical Oncology

---

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

Article Abstract:

A method for imaging the inhibition of Hsp90 by 17-allylaminogeldanamycin (17-AAG) is developed and used to quantify as a function of time, the loss and recovery of HER2 induced by 17-AAG in animal tumors. This method allows noninvasive imaging of the pharmacodynamics of a targeted drug and also facilitates the rational design of combination therapy based on target inhibition.

Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Cancer & Cell R&D, Cancer research, Heat shock proteins, Oncology, Experimental

---

Similar abstracts:

• Abstracts: Altruism and the economic on non-profit organisations. Making Sense of Non-Profit Organisations. The sustainable growth rate of non-profit organisations: the effect of efficiency, profitability and capital structure
• Abstracts: Factors explaining the inefficient valuation of intangibles. Intellectual capital and the capital market - organization and competence
• Abstracts: The changing attitude of European VCs. Next-generation monoclonals less profitable than trailblazers?
• Abstracts: Executive turnover in UK firms: the impact of Cadbury. What has the invisible hand achieved? A unified approach to the measurement of international accounting harmony
• Abstracts: Tests of the expectations hypothesis: resolving the anomalies when the short-term rate is the federal funds rate

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.